Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

inhalation aerosol Articles

Teva's ProAir approved for four-year olds

29 September 2008

Symbicort sees similar safety to budesonide

1 September 2008

AZ submits sNDA for Symbicot in pediatric asthma

9 June 2008

FDA says CFC inhalers will cease end 2008

9 June 2008

EPO revokes a Symbicort patent

12 May 2008

AstraZeneca submits Symbicort sNDA to US FDA

5 May 2008

Nycomed licenses US rights to ciclesonide drugs to Sepracor in deal worth up to $430M

4 February 2008

Teva enters drug alliance with UCB in USA

21 January 2008

FDA approves GSK's Flovent in children aged four to 11

27 March 2006

FDA OKs Sepracor's Xophenex metered-dose inhaler

21 March 2005

Aventis sells Azmacort to Kos for $200m

15 March 2004

IVAX expands US asthma products line with 3M's QVAR brand

8 April 2002

Astra USA Wins Sex Allegations Appeal

16 September 1996

GW's Flovent Approved In USA

8 April 1996

BOEHRINGER INGELHEIM RECEIVES NOT APPROVABLE LETTER

14 March 1994

GLAXO'S SEREVENT GAINS US APPROVAL

14 February 1994

BOEHRINGER INGELHEIM GETS GO-AHEAD FOR US TRIALS

19 July 1993

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS